Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT
Tóm tắt
We assessed the validity of “perfusion-metabolism coupling” hypothesis in recurrent glioma with 13N-ammonia (13N-NH3) PET/CT and 18F-fluorodeoxyglucose (18F-FDG) PET/CT. Fifty-six consecutive patients (age, 38.8 ± 12.1 years; 62.5 % males) with histologically proven and previously treated glioma presenting with clinical suspicion of recurrence were prospectively enrolled and evaluated with 13N-NH3 PET/CT and 18F-FDG PET/CT. PET/CT images were evaluated both qualitatively and semiquantitatively. Tumor to white matter uptake ratio (T/W) and tumor to gray matter uptake ratio (T/G) were calculated and analyzed for both the modalities. A combination of clinico-radiological follow-up, repeated imaging, and biopsy (when available) were considered as the reference standard. Based on the reference standard, 27/56 patients had recurrence. 13N-NH3 PET/CT and 18F-FDG PET/CT were concordant in 55/56 patients. Overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 13N-NH3PET/CT were 77.8, 86.2, 84.0, 80.7, and 82.1 %, respectively, and for 18F-FDG PET/CT were 77.8, 89.7, 87.5, 81.2, and 83.9 %, respectively. There was excellent agreement between results of 13N-NH3 PET/CT and 18F-FDG PET/CT (ĸ = 0.964; P < 0.001). The performances of 13N-NH3 PET/CT and 18F-FDG PET/CT were not significantly different between high-grade and low-grade glioma (P = 1.000). A strong positive correlation was noted between the uptake ratios derived on the two modalities (ρ = 0.866, P < 0.001 for T/W; ρ = 0.918, P < 0.001 for T/G). A combination of 13N-NH3 PET/CT and 18F-FDG PET/CT demonstrates that perfusion and metabolism are coupled in recurrent gliomas. These tracers target two different but interrelated aspects of the same pathologic process and can be used as surrogates for each other.
Tài liệu tham khảo
Shah AH, Snelling B, Bregy A, Patel PR, Tememe D, Bhatia R et al (2013) Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? J Neurooncol 112:141–152
Nihashi T, Dahabreh IJ, Terasawa T (2013) Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 34:944–950
Alexiou GA, Tsiouris S, Kyritsis AP, Voulgaris S, Argyropoulou MI, Fotopoulos AD (2009) Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 95:1–11
Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379:1984–1996
Mrugala MM, Kesari S, Ramakrishna N, Wen PY (2004) Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 4:759–782
Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP (1998) Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 19:407–413
Asensio C, Pérez-Castejón MJ, Maldonado A, Montz R, Ruiz JA, Santos M et al (1998) The role of PET-FDG in questionable diagnosis of relapse in the presence of radionecrosis of brain tumors. Rev Neurol 27:447–452
Xu JL, Shi DP, Dou S, Li YL, Yan F (2011) Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion weighted imaging. J Med Imaging Radiat Oncol 55:587–594
Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP et al (2012) Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 33:69–76
Xiangsong Z, Weian C (2007) Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol 82:305–311
Khangembam BC, Sharma P, Karunanithi S, Singhal A, Das CJ, Kumar P et al (2013) 13N ammonia PET/CT for detection of recurrent gioma: a prospective comparison with contrast enhanced MRI. Nucl Med Commun 34:1046–1054
Kumar R, Singh H, Jacob M, Anand SP, Bandopadhyaya GP (2009) Production of nitrogen-13-labeled ammonia by using 11 MeV medical cyclotron: our experience. Hell J Nucl Med 12:248–250
Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S (1993) Glucose consumption in recurrentgliomas. Neurosurgery 33:28–33
Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ et al (1988) Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 150:189–197
Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191–197
Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A (2011) F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study. Neuroradiology 53:1017–1024
Mineura K, Yasuda T, Kowada M, Shishido F, Ogawa T, Uemura K (1986) In vivo measurements of regional cerebral hemocirculation and metabolism in gliomas using 15O and 18F-fluorodeoxyglucose positron emission tomography. No To Shinkei 38:337–344
Phelps ME, Hoffman EJ, Coleman RE, Welch MJ, Raichle ME, Weiss ES et al (1976) Tomographic images of blood pool and perfusion in brain and heart. J Nucl Med 17:603–612
Phelps ME, Huang SC, Hoffman EJ, Selin C, Kuhl DE (1981) Cerebral extraction of N-13 ammonia: its dependence on cerebral blood flow and capillary permeability-surface area product. Stroke 12:607–619
Ott P, Larsen FS (2004) Blood–brain barrier permeability to ammonia in liver failure, a critical reappraisal. Neurochem Int 44:185–198
Yamamoto H, Konno H, Yamamoto T, Ito K, Mizugaki M, Iwasaki Y (1987) Glutamine synthetase of the human brain: purification and characterization. J Neurochem 49:603–609
Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DLA et al (2007) Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 188:204–212
McCormick D, McQuaid S, McCusker C, Allen IV (1990) A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol 16:205–211
Xuereb GP, Prichard ML, Daniel PM (1954) The hypophysial portal system of vessels in man. Q J Exp Physiol Cogn Med Sci 39:219–230
Wang X, Zhang S, Ye Y, Chen Y, Liu X (2012) Clinicopathologic features of delayed radiation-induced brain injury after radiotherapy for brain tumor. Zhonghua Bing Li Xue Za Zhi 41:224–228
Yoshii Y (2008) Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 25:51–58
Kureshi SA, Hofman FM, Schneider JH, Chin LS, Apuzzo ML, Hinton DR (1994) Cytokine expression in radiation-induced delayed cerebral injury. Neurosurgery 35:822–829
Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767–775
Okamoto Y, Di Patre P-L, Burkhard C, Horstmann S, Jourde B, Fahey M et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56
Wang SX, Boethius J, Ericson K (2006) FDG-PET on irradiated brain tumor: ten years’ summary. Acta Radiol 47:85–90
Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z et al (2013) The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med 38:522–526
Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R et al (2013) 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 40:1025–1035
Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MMD et al (2012) Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 37:158–163
Yamamoto Y, Ono Y, Aga F, Kawai N, Kudomi N, Nishiyama Y (2012) Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med 53:1911–1915
Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ et al (2006) Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47:393–403
Schierz JH, Opfermann T, Steenbeck J, Lopatta E, Settmacher U, Stallmach A et al (2013) Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions. J Nucl Med 54:848–854